For example, talimogene laherparepvec (T-VEC) is a genetically modified HSV-1 encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) that was approved by the U.S Food and Drug Administration and the European Medicine Agency in 2015 for the treatment of advanced melanoma [150,152]. This evidence concerns the gene CSF2 and melanoma.